Annual CFF
$1.03 M
-$94.73 M-98.92%
31 December 2023
Summary:
Immunic annual cash flow from financing activities is currently $1.03 million, with the most recent change of -$94.73 million (-98.92%) on 31 December 2023. During the last 3 years, it has fallen by -$143.40 million (-99.28%). IMUX annual CFF is now -99.28% below its all-time high of $144.43 million, reached on 31 December 2020.IMUX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$0.00
$0.000.00%
30 September 2024
Summary:
Immunic quarterly cash flow from financing activities is currently $0.00, unchanged on 30 September 2024. Over the past year, it has dropped by -$282.00 thousand (-100.00%). IMUX quarterly CFF is now -100.00% below its all-time high of $96.54 million, reached on 30 September 2020.IMUX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$75.07 M
-$282.00 K-0.37%
30 September 2024
Summary:
Immunic TTM cash flow from financing activities is currently $75.07 million, with the most recent change of -$282.00 thousand (-0.37%) on 30 September 2024. Over the past year, it has increased by +$18.60 million (+32.93%). IMUX TTM CFF is now -48.03% below its all-time high of $144.43 million, reached on 31 December 2020.IMUX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IMUX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -98.9% | -100.0% | +32.9% |
| 3 y3 years | -99.3% | -100.0% | +49.7% |
| 5 y5 years | +10000.0% | -100.0% | +148.7% |
IMUX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -99.3% | at low | -100.0% | -21.6% | +7167.0% | |
| 5 y | 5 years | -99.3% | >+9999.0% | -100.0% | -48.0% | +7167.0% | |
| alltime | all time | -99.3% | >+9999.0% | -100.0% | +100.0% | -48.0% | >+9999.0% |
Immunic Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(0.0%) | $75.07 M(-0.4%) |
| June 2024 | - | $0.00(-100.0%) | $75.35 M(-0.1%) |
| Mar 2024 | - | $74.46 M(>+9900.0%) | $75.45 M(+7203.6%) |
| Dec 2023 | $1.03 M(-98.9%) | $604.00 K(+114.2%) | $1.03 M(-98.2%) |
| Sept 2023 | - | $282.00 K(+193.8%) | $56.47 M(+0.5%) |
| June 2023 | - | $96.00 K(+88.2%) | $56.19 M(-15.1%) |
| Mar 2023 | - | $51.00 K(-99.9%) | $66.17 M(-30.9%) |
| Dec 2022 | $95.76 M(+123.5%) | $56.04 M(>+9900.0%) | $95.76 M(+136.2%) |
| Sept 2022 | - | $0.00(-100.0%) | $40.54 M(-50.9%) |
| June 2022 | - | $10.08 M(-66.0%) | $82.56 M(+13.9%) |
| Mar 2022 | - | $29.64 M(+3510.6%) | $72.48 M(+69.2%) |
| Dec 2021 | $42.84 M(-70.3%) | $821.00 K(-98.0%) | $42.84 M(-14.5%) |
| Sept 2021 | - | $42.02 M(>+9900.0%) | $50.13 M(-52.1%) |
| June 2021 | - | $0.00(0.0%) | $104.65 M(-27.3%) |
| Mar 2021 | - | $0.00(-100.0%) | $143.86 M(-0.4%) |
| Dec 2020 | $144.43 M(+313.9%) | $8.11 M(-91.6%) | $144.43 M(+2.4%) |
| Sept 2020 | - | $96.54 M(+146.2%) | $141.03 M(+215.4%) |
| June 2020 | - | $39.21 M(+6803.5%) | $44.71 M(+199.4%) |
| Mar 2020 | - | $568.00 K(-87.9%) | $14.93 M(-57.2%) |
| Dec 2019 | $34.90 M(>+9900.0%) | $4.71 M(+2010.8%) | $34.90 M(+15.6%) |
| Sept 2019 | - | $223.00 K(-97.6%) | $30.19 M(+0.7%) |
| June 2019 | - | $9.43 M(-54.0%) | $29.99 M(+45.8%) |
| Mar 2019 | - | $20.53 M(>+9900.0%) | $20.57 M(>+9900.0%) |
| Dec 2018 | $4000.00 | $0.00(-100.0%) | $4000.00(-99.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | $28.00 K(+366.7%) | $544.00 K(+60.0%) |
| June 2018 | - | $6000.00(-120.0%) | $340.00 K(+165.6%) |
| Mar 2018 | - | -$30.00 K(-105.6%) | $128.00 K(-99.7%) |
| Dec 2017 | $37.98 M(+207.0%) | $540.00 K(-406.8%) | $37.98 M(-1.5%) |
| Sept 2017 | - | -$176.00 K(-14.6%) | $38.55 M(-6.3%) |
| June 2017 | - | -$206.00 K(-100.5%) | $41.16 M(-10.3%) |
| Mar 2017 | - | $37.83 M(+3313.9%) | $45.87 M(+270.7%) |
| Dec 2016 | $12.37 M(-61.8%) | $1.11 M(-54.4%) | $12.37 M(-71.7%) |
| Sept 2016 | - | $2.43 M(-46.1%) | $43.73 M(+6.4%) |
| June 2016 | - | $4.51 M(+4.2%) | $41.12 M(+12.3%) |
| Mar 2016 | - | $4.33 M(-86.7%) | $36.61 M(+12.9%) |
| Dec 2015 | $32.42 M(-69.7%) | $32.47 M(<-9900.0%) | $32.42 M(-3.7%) |
| Sept 2015 | - | -$182.00 K(+4450.0%) | $33.68 M(-0.5%) |
| June 2015 | - | -$4000.00(-102.9%) | $33.84 M(-62.0%) |
| Mar 2015 | - | $139.00 K(-99.6%) | $88.98 M(-16.8%) |
| Dec 2014 | $106.92 M(+111.9%) | $33.72 M(<-9900.0%) | $106.92 M(+17.6%) |
| Sept 2014 | - | -$18.00 K(-100.0%) | $90.88 M(+1.6%) |
| June 2014 | - | $55.14 M(+205.1%) | $89.44 M(+35.1%) |
| Mar 2014 | - | $18.07 M(+2.2%) | $66.21 M(+31.2%) |
| Dec 2013 | $50.45 M(+83.4%) | $17.69 M(-1314.8%) | $50.45 M(+54.0%) |
| Sept 2013 | - | -$1.46 M(-104.6%) | $32.76 M(-4.3%) |
| June 2013 | - | $31.90 M(+1280.4%) | $34.21 M(+1380.4%) |
| Mar 2013 | - | $2.31 M | $2.31 M |
| Dec 2012 | $27.50 M(+233.2%) | - | - |
| Dec 2011 | $8.25 M | - | - |
FAQ
- What is Immunic annual cash flow from financing activities?
- What is the all time high annual CFF for Immunic?
- What is Immunic annual CFF year-on-year change?
- What is Immunic quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Immunic?
- What is Immunic quarterly CFF year-on-year change?
- What is Immunic TTM cash flow from financing activities?
- What is the all time high TTM CFF for Immunic?
- What is Immunic TTM CFF year-on-year change?
What is Immunic annual cash flow from financing activities?
The current annual CFF of IMUX is $1.03 M
What is the all time high annual CFF for Immunic?
Immunic all-time high annual cash flow from financing activities is $144.43 M
What is Immunic annual CFF year-on-year change?
Over the past year, IMUX annual cash flow from financing activities has changed by -$94.73 M (-98.92%)
What is Immunic quarterly cash flow from financing activities?
The current quarterly CFF of IMUX is $0.00
What is the all time high quarterly CFF for Immunic?
Immunic all-time high quarterly cash flow from financing activities is $96.54 M
What is Immunic quarterly CFF year-on-year change?
Over the past year, IMUX quarterly cash flow from financing activities has changed by -$282.00 K (-100.00%)
What is Immunic TTM cash flow from financing activities?
The current TTM CFF of IMUX is $75.07 M
What is the all time high TTM CFF for Immunic?
Immunic all-time high TTM cash flow from financing activities is $144.43 M
What is Immunic TTM CFF year-on-year change?
Over the past year, IMUX TTM cash flow from financing activities has changed by +$18.60 M (+32.93%)